Posted by Michael Wonder on 05 Oct 2019
Fasenra approved in the US for self-administration in a new pre-filled auto-injector, the Fasenra Pen
4 October 2019 - Fasenra is now the only respiratory biologic that offers the choice of administration at home or in a doctor’s office with eight-week maintenance dosing.
AstraZeneca today announced that the US FDA has approved the self-administration of Fasenra (benralizumab) in a pre-filled, single-use auto-injector (the Fasenra Pen).
The approval is supported by data from the Phase III GRECO trial and the Phase I AMES trial. The safety and tolerability of Fasenra in these trials were consistent with the established profile of the medicine.
